Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Circulation

• Publication date

  2000-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.101.6.594PMID 10673249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Nitric Oxide Regulates Renin Release During Salt Depletion but Does Not Alter Angiotensin Responses in Normal Humans

  1999cited by this paper
• Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?

  1999cited by this paper
• K+ is an endothelium-derived hyperpolarizing factor in rat arteries

  1998cited by this paper
• Endothelium as a therapeutic target in heart failure.

  1998cited by this paper
• Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients.

  1998cited by this paper
• Measuring forearm blood flow and interpreting the responses to drugs and mediators.

  1995cited by this paper
• Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta.

  1995cited by this paper
• C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity.

  1995cited by this paper
• Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration.

  1993cited by this paper
• Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone.

  1993cited by this paper
• Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses.

  1992cited by this paper
• Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo.

  1987cited by this paper

• Vascular (dys)function in the failing heart

  2025cites this paper
• Life-saving Drug or Potential Threat? The Role of Mineralocorticoid Receptor Antagonists in Myocardial Infarction: A Meta-Analysis.

  2025cites this paper
• Safety and efficacy of early use of mineralocorticoid receptor antagonists in cardiogenic shock: a propensity score-matched analysis

  2025cites this paper
• Occurrence of Metabolic Disorders in Bilateral Primary Aldosteronism Compared to Unilateral Primary Aldosteronism

  2025cites this paper
• Adulterated dietary supplements commercialized in Brazil: development of a screening method and a preliminary study of cytotoxicity

  2024cites this paper
• Prevalence, Risk Factors, and Management of Conn's syndrome; A Systematic Review

  2024cites this paper
• Familial Hyperaldosteronism: an ENDO ERN Clinical Practice Guideline.

  2024cites this paper
• Additive Effects of Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker, on Cardioplegic Arrest in Rat Hearts

  2024cites this paper
• Leukocyte–endothelial interaction in CKD

  2023cites this paper
• Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management

  2023cites this paper
• Inflammation in Diabetic Kidney Disease: Focus on New Therapeutic Considerations

  2023cites this paper
• Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure

  2023cites this paper
• Effect of esaxerenone on ischemia and reperfusion injury in rat hearts.

  2023cites this paper
• Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease

  2023cites this paper
• Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease

  2023cites this paper
• Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine‐based delivery applications and future trends

  2022cites this paper
• Elevated Myoglobin in Patients With Primary Aldosteronism: A Cross-Sectional Study

  2022cites this paper
• Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Spirolactone-type and enmein-type derivatives as potential anti-cancer agents derived from oridonin.

  2022cites this paper
• Themed Issue: Emerging Fields for Therapeutic Targeting of the Aldosterone-Mineralocorticoid Receptor Signaling Pathway

  2022cites this paper
• Drug-Induced Rhinitis: Narrative Review

  2022cites this paper
• A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice

  2022cites this paper
• Sarcopenia as a comorbidity of cardiovascular disease.

  2021cites this paper
• Glutaminolysis: A Driver of Vascular and Cardiac Remodeling in Pulmonary Arterial Hypertension

  2021cites this paper
• Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging

  2021cites this paper
• Modification of ventriculo–arterial coupling by spironolactone in nonischemic dilated cardiomyopathy

  2021cites this paper
• Current and emerging drug targets in heart failure treatment

  2021cites this paper
• Kardioprotektion durch selektive Aldosteronblockade

  2021cites this paper
• Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF

  2021cites this paper
• Pharmacology of Antihypertensive Drugs

  2020cites this paper
• Enantioselective Radical-Polar Crossover Reactions of Indanonecarboxamides with Alkenes.

  2020cites this paper
• Hypertension in the Dog and Cat

  2020cites this paper
• Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension

  2020cites this paper
• Kardioprotektion durch selektive Aldosteronblockade

  2020cites this paper
• The Vascular Consequences of Metabolic Syndrome: Rodent Models, Endothelial Dysfunction, and Current Therapies

  2020cites this paper
• Spironolactone in pulmonary arterial hypertension: results of a cross-over study

  2020cites this paper
• Alterations in the Peripheral Circulation in Heart Failure

  2020cites this paper
• Use of Diuretics in Chronic Kidney Disease Patients

  2020cites this paper
• Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone

  2020cites this paper
• Endothelial Dysfunction in Primary Aldosteronism

  2019cites this paper
• The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.

  2019cites this paper
• Dinuclear Zinc-Catalyzed Asymmetric Tandem Reaction of α-Hydroxy-1-indanone: Access to Spiro[1-indanone-5,2'-γ-butyrolactones].

  2019cites this paper
• Mineralocorticoid Receptor Antagonists in the Treatment of Coronary Artery Disease, Myocardial Infarction and Heart Failure

  2019cites this paper
• Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

  2019cites this paper
• University of Southern Denmark Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients

  2019cites this paper
• Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging

  2019cites this paper
• The Differential Effect of Excess Aldosterone on Skeletal Muscle Mass by Sex

  2019influential citation
• Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men’s Issue?

  2019cites this paper
• Association of spironolactone treatment and arterial stiffness and cardiovascular disease in hypertensive patients

  2019cites this paper
• Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism.

  2019cites this paper
• Novel role of spironolactone in the therapy of resistant hypertension: Spironolactone and resistant hypertension

  2019cites this paper
• Endothelial Dysfunction in Chronic Heart Failure: Assessment, Findings, Significance, and Potential Therapeutic Targets

  2019influential citation
• Mineralocorticoid Receptors in Metabolic Syndrome: From Physiology to Disease.

  2019cites this paper
• Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients

  2019cites this paper
• The Endothelial Mineralocorticoid Receptor: Contributions to Sex Differences in Cardiovascular Disease.

  2019cites this paper
• Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone.

  2019cites this paper
• The Role of Vasodilator Receptors of Renin–angiotensin System on Nitric Oxide Formation and Kidney Circulation after Angiotensin II Infusion in Renal Ischemia/Reperfusion Rats

  2018cites this paper
• Spironolactone voltammetric determination on renewable amalgam film electrode

  2018cites this paper
• Acylated ghrelin protects aorta damage post-MI via activation of eNOS and inhibition of angiotensin-converting enzyme induced activation of NAD(P)H-dependent oxidase

  2018cites this paper
• Novel interventional therapies to improve cardiovascular risk in women with polycystic ovary syndrome

  2018cites this paper
• The Effect of Spironolactone on Cerebral Blood Flow and Cognition

  2018cites this paper
• Mineralocorticoid receptor blockade improves arginine transport and nitric oxide generation through modulation of cationic amino acid transporter-1 in endothelial cells.

  2018cites this paper
• Periarterial fat from two human vascular beds is not a source of aldosterone to promote vasoconstriction.

  2018cites this paper
• Neurohormonal Axis and Natriuretic Peptides in Heart Failure

  2018cites this paper
• Timing of Left Ventricular Remodeling in Nonischemic Dilated Cardiomyopathy

  2018cites this paper
• The Effect of Mineralocorticoid Receptor Antagonists on Recruitment and Function of Endothelial Progenitor Cells in Patients with Congestive Heart Failure.

  2018cites this paper
• Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-&kgr;B and AP-1 signalling

  2018cites this paper
• Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome

  2018cites this paper
• Update in diagnosis and management of primary aldosteronism

  2017cites this paper
• Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension

  2017cites this paper
• Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials

  2017cites this paper
• Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists

  2017cites this paper
• Impact of Adrenal Steroids on Regulation of Adipose Tissue.

  2017cites this paper
• The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease

  2016cites this paper
• Mineralocorticoid receptor antagonists in dialysis patients

  2016cites this paper
• The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

  2016cites this paper
• Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.

  2016cites this paper
• Does Aldosterone Play a Significant Role for Regulation of Vascular Tone?

  2016cites this paper
• An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.

  2016cites this paper
• eneric Drugs in Cardiology : ill They Reduce Health Care Costs ?

  2016cites this paper
• The renin–angiotensin–aldosterone-system and right heart failure in congenital heart disease

  2016cites this paper
• Modulation of Vascular ACE by Oxidative Stress in Young Syrian Cardiomyopathic Hamsters: Therapeutic Implications

  2016cites this paper
• Antimicrobial Inhibitory Activities of Phenolic Extracts from Four Selected Soybean Hulls in Culture and Chicken Skin Model Systems, and Preliminary ACE-Inhibitory Activity

  2016cites this paper
• Beneficis cardiovasculars de la correcció De L’anèmia amb eritropoetina en els malalts amb insuficiència renal crònica prediàlisi. Influència de l’estrès oxidatiu, la inflamació i el Nt-Probnp

  2016cites this paper
• Long‐Term Effects of Low‐Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo‐Controlled Study

  2016cites this paper
• Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double‐Blind, Randomized, Placebo‐Controlled Trial

  2016cites this paper
• Congestive Heart Failure Beneficial Neurohormonal Profile of Spironolactone in Severe Congestive Heart Failure

  2016cites this paper
• WITHDRAWN: Diuretics for heart failure.

  2016cites this paper
• Issues in the Diagnosis and Treatment of Primary Aldosteronism

  2016cites this paper
• Endothelial dysfunction in human essential hypertension.

  2016cites this paper
• Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis

  2016cites this paper
• Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association.

  2015cites this paper
• Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.

  2015cites this paper
• Current and Future Strategies for the Diagnosis and Treatment of Cardiac Fibrosis

  2015cites this paper
• Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure

  2015cites this paper
• Bloqueo de los receptores de mineralocorticoides y estimulación del sistema incretina en el tratamiento de la miocardiopatía diabética experimental

  2015cites this paper
• Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?

  2015cites this paper
• Association between aldosterone synthase (CYP11B2) -344C/T polymorphism and atrial fibrillation among Han and Kazak residents of the Xinjiang region.

  2015cites this paper
• Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease.

  2015cites this paper
• Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism

  2015cites this paper